380 related articles for article (PubMed ID: 15607966)
1. Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells.
Valsesia-Wittmann S; Magdeleine M; Dupasquier S; Garin E; Jallas AC; Combaret V; Krause A; Leissner P; Puisieux A
Cancer Cell; 2004 Dec; 6(6):625-30. PubMed ID: 15607966
[TBL] [Abstract][Full Text] [Related]
2. [Cancer cells escape from failsafe programs in a simple Twist].
Puisieux A; Valsesia-Wittmann S
Bull Cancer; 2006 Mar; 93(3):251-6. PubMed ID: 16567311
[TBL] [Abstract][Full Text] [Related]
3. E2F activity is essential for survival of Myc-overexpressing human cancer cells.
Santoni-Rugiu E; Duro D; Farkas T; Mathiasen IS; Jäättelä M; Bartek J; Lukas J
Oncogene; 2002 Sep; 21(42):6498-509. PubMed ID: 12226753
[TBL] [Abstract][Full Text] [Related]
4. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
[TBL] [Abstract][Full Text] [Related]
5. Bcl-2 is an apoptotic target suppressed by both c-Myc and E2F-1.
Eischen CM; Packham G; Nip J; Fee BE; Hiebert SW; Zambetti GP; Cleveland JL
Oncogene; 2001 Oct; 20(48):6983-93. PubMed ID: 11704823
[TBL] [Abstract][Full Text] [Related]
6. Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas.
Silva J; García JM; Peña C; García V; Domínguez G; Suárez D; Camacho FI; Espinosa R; Provencio M; España P; Bonilla F
Clin Cancer Res; 2006 Dec; 12(23):6929-36. PubMed ID: 17145810
[TBL] [Abstract][Full Text] [Related]
7. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins.
Bucci B; D'Agnano I; Amendola D; Citti A; Raza GH; Miceli R; De Paula U; Marchese R; Albini S; Felsani A; Brunetti E; Vecchione A
Clin Cancer Res; 2005 Apr; 11(7):2756-67. PubMed ID: 15814658
[TBL] [Abstract][Full Text] [Related]
8. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc.
Datta A; Nag A; Pan W; Hay N; Gartel AL; Colamonici O; Mori Y; Raychaudhuri P
J Biol Chem; 2004 Aug; 279(35):36698-707. PubMed ID: 15199070
[TBL] [Abstract][Full Text] [Related]
9. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of AP-1 transcription activator induces myc-dependent apoptosis in HL60 cells.
Park S; Hahm ER; Lee DK; Yang CH
J Cell Biochem; 2004 Apr; 91(5):973-86. PubMed ID: 15034932
[TBL] [Abstract][Full Text] [Related]
11. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.
Hemann MT; Bric A; Teruya-Feldstein J; Herbst A; Nilsson JA; Cordon-Cardo C; Cleveland JL; Tansey WP; Lowe SW
Nature; 2005 Aug; 436(7052):807-11. PubMed ID: 16094360
[TBL] [Abstract][Full Text] [Related]
12. Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplification.
Roy Choudhury S; Karmakar S; Banik NL; Ray SK
Invest New Drugs; 2010 Dec; 28(6):812-24. PubMed ID: 19777160
[TBL] [Abstract][Full Text] [Related]
13. Induced p21WAF1 expression acts to reverse myc myelomonocytic cell transformation.
Dolnikov A; Millington M; Sun LQ; Symonds G
Cancer Gene Ther; 2000 Nov; 7(11):1491-503. PubMed ID: 11129291
[TBL] [Abstract][Full Text] [Related]
14. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
15. MYC phosphorylation at novel regulatory regions suppresses transforming activity.
Wasylishen AR; Chan-Seng-Yue M; Bros C; Dingar D; Tu WB; Kalkat M; Chan PK; Mullen PJ; Huang L; Meyer N; Raught B; Boutros PC; Penn LZ
Cancer Res; 2013 Nov; 73(21):6504-15. PubMed ID: 24030976
[TBL] [Abstract][Full Text] [Related]
16. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
17. N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells.
Ushmorov A; Hogarty MD; Liu X; Knauss H; Debatin KM; Beltinger C
Oncogene; 2008 May; 27(24):3424-34. PubMed ID: 18193081
[TBL] [Abstract][Full Text] [Related]
18. The ARF tumor suppressor: keeping Myc on a leash.
Gregory MA; Qi Y; Hann SR
Cell Cycle; 2005 Feb; 4(2):249-52. PubMed ID: 15655352
[TBL] [Abstract][Full Text] [Related]
19. DNA-damaging drug-induced apoptosis sensitized by N-myc in neuroblastoma cells.
Li T; Wang L; Ke XX; Gong XY; Wan JH; Hao XW; Xu M; Xiang Z; Cui ZB; Cui H
Cell Biol Int; 2012 Apr; 36(4):331-7. PubMed ID: 21929510
[TBL] [Abstract][Full Text] [Related]
20. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma.
Regan PL; Jacobs J; Wang G; Torres J; Edo R; Friedmann J; Tang XX
Int J Oncol; 2011 Jan; 38(1):105-12. PubMed ID: 21109931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
